EpiCast Report: Myasthenia Gravis - Epidemiology Forecast to 2024
Myasthenia gravis is an autoimmune disease that affects the nerves and muscles and is characterized by muscle weakness and fatigue, especially weakness of the muscles controlling eye and eyelid movement, facial expression, chewing and talking. In some cases the muscles controlling breathing are also affected, which can lead to respiratory failure that requires intubation and mechanical ventilation, known as a myasthenic crisis. The muscle weakness seen in myasthenia gravis is most often caused by circulating antibodies that mistakenly attack healthy tissue and inhibit normal neuromuscular transmission by blocking or damaging muscle receptor cells.
GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of myasthenia gravis in the 7MM, from 106,845 cases in 2014 to 119,939 cases in 2024, at an Annual Growth Rate (AGR) of 1.23% in the forecast period. The highest number of diagnosed prevalent cases of myasthenia gravis fell into the =75 year age group in the 7MM. The majority of diagnosed prevalent cases of myasthenia gravis in the 7MM in 2014 were women. The US and the 5EU markets follow a similar pattern, in which Class III has the highest number of diagnosed prevalent cases. Japan, however, has more cases in Class II than any other Class.
To build the epidemiological forecast of myasthenia gravis in the 7MM, GlobalData epidemiologists reviewed the literature and obtained country-specific, population-based studies that reported myasthenia gravis prevalence as determined via medical record reviews. GlobalData epidemiologists obtained country-specific diagnosed prevalence data for the US, Italy, the UK, and Japan, thereby providing valuable analysis of epidemiological trends amongst the 7MM. This forecast also includes age- and sex-specific segmentations, thereby providing detailed information about the characteristic of the disease in each market.
- The Myasthenia Gravis EpiCast Report provides an overview of the risk factors and global trends of myasthenia gravis in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of myasthenia gravis, segmented by sex, age, and Myasthenia Gravis Foundation of America (MGFA) classifications (Class I, Class II, Class III, Class IV, and Class V).
- The myasthenia gravis epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy
The Myasthenia Gravis EpiCast series will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global myasthenia gravis market.
- Quantify patient populations in the global myasthenia gravis market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for myasthenia gravis therapeutics in each of the markets covered.
- Identify the percentage of myasthenia gravis prevalent cases by class.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 4
1.2 List of Figures 5
2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global Trends 10
3.4 Forecast Methodology 11
3.4.1 Sources Used 14
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods 17
3.5 Epidemiological Forecast of Myasthenia Gravis (2014-2024) 21
3.5.1 Diagnosed Prevalent Cases of Myasthenia Gravis 21
3.5.2 Age-Specific Diagnosed PrevaIent Cases of Myasthenia Gravis 23
3.5.3 Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis 24
3.5.4 Age-Standardized Diagnosed Prevalence of Myasthenia Gravis 26
3.5.5 Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Class 27
3.6 Discussion 28
3.6.1 Epidemiological Forecast Insight 28
3.6.2 Limitations of the Analysis 29
3.6.3 Strengths of the Analysis 29
4 Appendix 30
4.1 Bibliography 30
4.2 About the Authors 33
4.2.1 Epidemiologists 33
4.2.2 Reviewers 33
4.2.3 Global Director of Therapy Analysis and Epidemiology 34
4.2.4 Global Head of Healthcare 35
4.3 About GlobalData 35
4.4 About EpiCast 36
4.5 Disclaimer 36
1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Myasthenia Gravis 9
Table 2: Global Estimates for the Diagnosed Prevalence of Myasthenia Gravis 11
Table 3: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Myasthenia Gravis 12
Table 4: 7MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Myasthenia Gravis Segmented by MGFA Classifications 13
Table 5: 8MM, Sources Not Used in Epidemiological Analysis of Myasthenia Gravis 17
Table 6: 7MM, Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, All Ages, N, Select Years 2014-2024 22
Table 7: 7MM, Age-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, N (Row %), 2014 23
Table 8: 7MM: Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, All Ages, N (Row %), 2014 25
1.2 List of Figures
Figure 1: 7MM, Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, All Ages, N, 2014-2024 22
Figure 2: 7MM, Age-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, Both Sexes, N, 2014 24
Figure 3: 7MM, Sex-Specific Diagnosed Prevalent Cases of Myasthenia Gravis, All Ages, 2014 26
Figure 4: 7MM, Age-Standardized Diagnosed Prevalence of Myasthenia Gravis (Cases per 100,000 Population), Both Sexes, All Ages, 2014 27
Figure 5: 7MM, Diagnosed Prevalent Cases of Myasthenia Gravis by MGFA Class, Both Sexes, All Ages, N, 2014 28